WO1999006554A3 - 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES - Google Patents

5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES Download PDF

Info

Publication number
WO1999006554A3
WO1999006554A3 PCT/IB1998/001238 IB9801238W WO9906554A3 WO 1999006554 A3 WO1999006554 A3 WO 1999006554A3 IB 9801238 W IB9801238 W IB 9801238W WO 9906554 A3 WO9906554 A3 WO 9906554A3
Authority
WO
WIPO (PCT)
Prior art keywords
ests
secreted proteins
muscle
proteins expressed
mesodermal tissues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1998/001238
Other languages
French (fr)
Other versions
WO1999006554A2 (en
WO1999006554B1 (en
Inventor
Milne Edwards Jean-Bapti Dumas
Aymeric Duclert
Bruno Lacroix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset SA filed Critical Genset SA
Priority to CA002297109A priority Critical patent/CA2297109A1/en
Priority to JP2000505295A priority patent/JP2001512016A/en
Priority to AU85557/98A priority patent/AU8555798A/en
Priority to EP98936596A priority patent/EP1000152A2/en
Publication of WO1999006554A2 publication Critical patent/WO1999006554A2/en
Publication of WO1999006554A3 publication Critical patent/WO1999006554A3/en
Anticipated expiration legal-status Critical
Publication of WO1999006554B1 publication Critical patent/WO1999006554B1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The sequences of 5' ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5' ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5' ESTs. The 5' ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5' ESTs. The 5' ESTs may also be used to design expression vectors and secretion vectors.
PCT/IB1998/001238 1997-08-01 1998-07-31 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES Ceased WO1999006554A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002297109A CA2297109A1 (en) 1997-08-01 1998-07-31 5' ests for secreted proteins expressed in muscle and other mesodermal tissues
JP2000505295A JP2001512016A (en) 1997-08-01 1998-07-31 5'EST of secreted proteins expressed in muscle and other mesodermal tissues
AU85557/98A AU8555798A (en) 1997-08-01 1998-07-31 5' ests for secreted proteins expressed in muscle and other mesodermal tissues
EP98936596A EP1000152A2 (en) 1997-08-01 1998-07-31 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90513497A 1997-08-01 1997-08-01
US08/905,134 1997-08-01

Publications (3)

Publication Number Publication Date
WO1999006554A2 WO1999006554A2 (en) 1999-02-11
WO1999006554A3 true WO1999006554A3 (en) 1999-05-27
WO1999006554B1 WO1999006554B1 (en) 2001-05-31

Family

ID=25420335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/001238 Ceased WO1999006554A2 (en) 1997-08-01 1998-07-31 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES

Country Status (5)

Country Link
EP (2) EP1367124A1 (en)
JP (1) JP2001512016A (en)
AU (1) AU8555798A (en)
CA (1) CA2297109A1 (en)
WO (1) WO1999006554A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076086B2 (en) 1999-06-29 2011-12-13 Millennium Pharmaceuticals, Inc. Methods of modulating the activity of TANGO332

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
ES2274574T3 (en) * 1997-08-01 2007-05-16 Schering Corporation MAMPHEROUS CELLULAR MEMBRANE PROTEINS; RELATED REAGENTS.
JP2001515720A (en) * 1997-09-10 2001-09-25 ザイモジェネティクス，インコーポレイティド β-defensin
US6576755B1 (en) 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
US20020102542A1 (en) 1997-10-07 2002-08-01 Daikichi Fukushima Polypeptide, cdna encoding the polypeptide, and use of the both
DE69933044T3 (en) 1998-11-27 2016-11-24 Ucb Pharma, S.A. Compositions and methods for increasing bone mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AU2373800A (en) * 1998-12-11 2000-06-26 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
US7078203B1 (en) 1999-03-31 2006-07-18 The University Of North Carolina At Chapel Hill Isolated DNA encoding cullin regulators ROC1 and ROC2, isolated proteins encoded by the same, and methods utilizing the same
EP1988165A1 (en) * 1999-03-31 2008-11-05 The University of North Carolina at Chapel Hill Isolated DNA encoding cullin regulator ROC1, isolated proteins encoded by the same, and methods utilizing the same
US20020037513A1 (en) * 2000-03-24 2002-03-28 Rosana Kapeller-Libermann 33338, a novel human ubiquitin hydrolase-like molecule and uses thereof
US6569667B1 (en) 2000-04-26 2003-05-27 Millennium Pharmaceuticals, Inc. 26335, a novel human serine/threonine dehydratase and uses thereof
US6979551B2 (en) 2000-04-03 2005-12-27 Rigel Pharmaceuticals, Inc. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
JP2002335964A (en) * 2000-04-27 2002-11-26 Takeda Chem Ind Ltd New protein and application thereof
US20050074754A1 (en) * 2000-04-27 2005-04-07 Shoichi Okubo Novel protein and use thereof
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20050014148A1 (en) * 2001-08-31 2005-01-20 Yongming Sun Compositions and methods relating to ovary specific genes and proteins
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
SMT202000095T1 (en) 2010-05-14 2020-03-13 Amgen Inc High concentration anti-sclerostin antibody formulations
EP2681242B1 (en) 2011-03-01 2018-01-24 Amgen Inc. Sclerostin and dkk-1 bispecific binding agents
WO2012135035A1 (en) 2011-03-25 2012-10-04 Amgen Inc. Anti - sclerostin antibody crystals and formulations thereof
CA2842432C (en) 2011-08-04 2022-10-04 Amgen Inc. Method for treating bone gap defects
SG11201403718YA (en) 2011-12-28 2014-07-30 Amgen Inc Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
US9925260B2 (en) 2012-07-05 2018-03-27 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
MA41142A (en) 2014-12-12 2017-10-17 Amgen Inc ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3774879B1 (en) 2018-03-30 2026-01-28 Amgen Inc. C-terminal antibody variants
CN110845572B (en) * 2019-11-28 2023-03-21 中国药科大学 Tumor-targeted GRP (glass-fiber reinforced Polypropylene) analogue and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625572A1 (en) * 1992-09-25 1994-11-23 The Kanagawa Academy Of Science And Technology Foundation PROCESS FOR SYNTHESIZING COMPLETE-LENGTH cDNA, PROCESS FOR PRODUCING INTERMEDIATE THEREFOR, AND PROCESS FOR PRODUCING RECOMBINANT VECTOR CONTAINING COMPLETE-LENGTH cDNA
WO1996034981A2 (en) * 1995-05-02 1996-11-07 Genset Sa METHOD FOR THE SPECIFIC COUPLING OF THE CAP OF THE EXTREMITY 5' OF A FRAGMENT mRNA AND PREPARATION OF mRNA AND COMPLETE cDNA
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby
WO1998042738A1 (en) * 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 human secreted proteins
WO1998044114A1 (en) * 1997-03-31 1998-10-08 Incyte Pharmaceuticals, Inc. Calcium-binding protein similar to reticulocalbin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625572A1 (en) * 1992-09-25 1994-11-23 The Kanagawa Academy Of Science And Technology Foundation PROCESS FOR SYNTHESIZING COMPLETE-LENGTH cDNA, PROCESS FOR PRODUCING INTERMEDIATE THEREFOR, AND PROCESS FOR PRODUCING RECOMBINANT VECTOR CONTAINING COMPLETE-LENGTH cDNA
WO1996034981A2 (en) * 1995-05-02 1996-11-07 Genset Sa METHOD FOR THE SPECIFIC COUPLING OF THE CAP OF THE EXTREMITY 5' OF A FRAGMENT mRNA AND PREPARATION OF mRNA AND COMPLETE cDNA
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby
WO1998042738A1 (en) * 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 human secreted proteins
WO1998044114A1 (en) * 1997-03-31 1998-10-08 Incyte Pharmaceuticals, Inc. Calcium-binding protein similar to reticulocalbin

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CARNINCI P. ET AL.: "High-efficiency full-length cDNA cloning by biotinylated CAP trapper", GENOMICS, vol. 37, no. 3, 1 November 1996 (1996-11-01), pages 327 - 336, XP002081729 *
Database EMBL Emest7, Entry HS1150166 Accession number AA232452 6 March 1997 96% identity with Seq.ID:38 nt.41-140 *
HEIJNE VON G.: "A new method for predicting signal sequence cleavage sites", NUCLEIC ACIDS RESEARCH, vol. 14, no. 11, 1986, pages 4683 - 4690, XP002053954 *
KATO S. ET AL.: "Construction of a human full-length cDNA bank", GENE, vol. 150, 1994, pages 243 - 250, XP002081364 *
LIN Y. ET AL.: "Inhibition of nuclear translocation of transcription factor NF-kB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 24, 16 June 1995 (1995-06-16), pages 14255 - 14258, XP002050723 *
OZAWA M.: "Cloning of a human homologue of mouse reticulocalbin reveals conservation of structural domains in the novel endoplasmic reticulum resident Ca2+-binding protein with multiple EF-hand motifs", JOURNAL OF BIOCHEMISTRY, vol. 117, 1995, pages 1113 - 1119, XP002070128 *
SCHÄFER B.W. AND HEIZMANN C.W.: "The S100 family of EF-hand calcium-binding proteins: functions and pathology", TIBS TRENDS IN BIOCHEMICAL SCIENCES, vol. 21, no. 4, April 1996 (1996-04-01), pages 134-140, XP004050923 *
TASHIRO K. ET AL.: "Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins", SCIENCE, vol. 261, 30 July 1993 (1993-07-30), pages 600 - 603, XP000673204 *
YOKOYAMA-KOBAYASHI M. ET AL.: "A signal sequence detection system using secreted protease activity as an indicator", GENE, vol. 163, 1995, pages 193 - 196, XP002053953 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076086B2 (en) 1999-06-29 2011-12-13 Millennium Pharmaceuticals, Inc. Methods of modulating the activity of TANGO332

Also Published As

Publication number Publication date
EP1367124A1 (en) 2003-12-03
WO1999006554A2 (en) 1999-02-11
EP1000152A2 (en) 2000-05-17
WO1999006554B1 (en) 2001-05-31
AU8555798A (en) 1999-02-22
CA2297109A1 (en) 1999-02-11
JP2001512016A (en) 2001-08-21

Similar Documents

Publication Publication Date Title
WO1999006554A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES
WO1999006548A3 (en) 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS
WO1999006552A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN BRAIN
WO1999053051A3 (en) 5' ests and encoded human proteins
WO1999006550A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE
EP1033401A3 (en) Expressed sequence tags and encoded human proteins
WO1999006549B1 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN TESTIS AND OTHER TISSUES
WO1999006551A3 (en) 5' ESTs FOR SECRETED PROTEINS IDENTIFIED FROM BRAIN TISSUES
WO1999006553A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN VARIOUS TISSUES
WO1999006439A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN ENDODERM
WO1999031236A3 (en) EXTENDED cDNAs FOR SECRETED PROTEINS
WO1999025825A3 (en) EXTENDED cDNAs FOR SECRETED PROTEINS
WO1999040189A3 (en) Cdnas encoding secreted proteins
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
WO1999054461A3 (en) Human nucleic acid sequences of endometrium tumour tissue
CA2253238A1 (en) Novel agouti-related gene
WO1998055508A3 (en) HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
WO1999054353A3 (en) Human nucleic acid sequences of normal uterus tissue
WO1999047655A3 (en) Human nucleic acid fragments with heightened expression in normal breast tissue
CA2210871A1 (en) Human dnase i variants
WO1997040134A3 (en) Human dnase ii
WO1999054446A3 (en) Human nucleic acid sequences which are overexpressed in normal pancreas tissue
EP1903111A3 (en) Extended cDNAs for secreted proteins
AU7433696A (en) Tyrosine kinase associated protein-1 (tka-1), nucleotide and amino acid sequences and their use in diagnosis and treatment of tka-1 related disorders
CA2242562A1 (en) Human dnase resistant to actin inhibition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2297109

Country of ref document: CA

Ref country code: CA

Ref document number: 2297109

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 85557/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998936596

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998936596

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG